Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLTNASDAQ:CLRBNASDAQ:CUENASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.32-1.0%$0.51$0.30▼$10.62$36.87M1.883.11 million shs1.29 million shsCLRBCellectar Biosciences$0.27+11.0%$0.31$0.22▼$3.73$12.57M0.671.15 million shs642,903 shsCUECue Biopharma$0.72+2.7%$1.08$0.45▼$2.26$44.44M2.02443,524 shs70,253 shsOKUROnKure Therapeutics$2.96-6.0%$4.80$2.57▼$20.00$39.77M0.3583,310 shs68,311 shsUnlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics+0.32%-22.73%-41.33%-53.34%-94.24%CLRBCellectar Biosciences+11.03%-6.96%-12.76%-3.37%-92.18%CUECue Biopharma+2.70%-5.50%-30.88%-52.40%-59.50%OKUROnKure Therapeutics-6.03%-23.91%-40.20%-60.16%+295,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.0733 of 5 stars3.33.00.04.72.72.50.6CLRBCellectar Biosciences2.1332 of 5 stars3.35.00.00.02.20.00.6CUECue Biopharma4.4697 of 5 stars3.55.00.04.73.30.81.3OKUROnKure Therapeutics2.8419 of 5 stars3.70.00.00.01.63.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,824.90% UpsideCLRBCellectar Biosciences 2.50Moderate Buy$12.504,482.11% UpsideCUECue Biopharma 3.00Buy$3.00317.36% UpsideOKUROnKure Therapeutics 3.40Buy$32.33992.34% UpsideCurrent Analyst Ratings BreakdownLatest CLRB, OKUR, CUE, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.003/11/2025OKUROnKure TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $30.00(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics-$212K-173.93N/AN/A($0.20) per share-1.58CLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/ACUECue Biopharma$9.29M4.78N/AN/A$0.82 per share0.88OKUROnKure TherapeuticsN/AN/AN/AN/A$26.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$1.61N/AN/AN/AN/A-260.75%-76.04%5/8/2025 (Estimated)CLRBCellectar Biosciences-$42.77M-$1.33N/AN/AN/AN/AN/A-191.22%5/13/2025 (Estimated)CUECue Biopharma-$50.73M-$0.75N/AN/AN/A-468.02%-156.38%-88.07%4/14/2025 (Estimated)OKUROnKure Therapeutics-$77.39M-$6.57N/AN/AN/AN/A-51.17%-47.11%5/6/2025 (Estimated)Latest CLRB, OKUR, CUE, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2024APLTApplied Therapeutics-$0.08N/AN/AN/A$0.10 millionN/A5/8/2025Q1 2025CUECue Biopharma-$0.15N/AN/AN/A$0.90 millionN/A5/6/2025N/AOKUROnKure Therapeutics-$1.41N/AN/AN/AN/AN/A4/14/2025Q4 2024CUECue Biopharma-$0.17N/AN/AN/A$1.70 millionN/A3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million3/10/2025Q4 2024OKUROnKure Therapeutics-$0.86-$1.37-$0.51-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.061.06CLRBCellectar BiosciencesN/A1.771.77CUECue Biopharma0.052.222.22OKUROnKure TherapeuticsN/A23.7123.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CLRBCellectar Biosciences16.41%CUECue Biopharma35.04%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics8.60%CLRBCellectar Biosciences3.70%CUECue Biopharma12.26%OKUROnKure Therapeutics17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30116.36 million106.35 millionOptionableCLRBCellectar Biosciences1046.08 million44.38 millionOptionableCUECue Biopharma6061.82 million55.58 millionOptionableOKUROnKure TherapeuticsN/A13.44 million2.75 millionN/ACLRB, OKUR, CUE, and APLT HeadlinesRecent News About These CompaniesWhy OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 19.54%April 6, 2025 | aaii.comAisling Capital Management LP Invests $762,000 in OnKure Therapeutics (NASDAQ:OKUR)April 3, 2025 | marketbeat.comHighbridge Capital Management LLC Makes New $3.44 Million Investment in OnKure Therapeutics (NASDAQ:OKUR)March 29, 2025 | marketbeat.comQ1 EPS Estimate for OnKure Therapeutics Decreased by AnalystMarch 21, 2025 | marketbeat.comOnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for OnKure Therapeutics (NASDAQ:OKUR) Stock PriceMarch 19, 2025 | marketbeat.comOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comPromising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025March 18, 2025 | tipranks.comWill OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?March 12, 2025 | finance.yahoo.comOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future ProspectsMarch 12, 2025 | tipranks.comOnKure Therapeutics Reports Progress and FinancialsMarch 12, 2025 | tipranks.comOnKure boosts R&D spending with cancer trial underwayMarch 12, 2025 | bizwest.comOnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)March 10, 2025 | markets.businessinsider.comOnKure Therapeutics price target lowered to $30 from $35 at OppenheimerMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Progress on PIKture-01 Trial and Expands PI3Ka Franchise with Upcoming Development Candidate AnnouncementMarch 10, 2025 | quiverquant.comOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | globenewswire.comOnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor ConferencesMarch 4, 2025 | globenewswire.comDeep Track Capital, LP Acquires Shares in OnKure Therapeutics IncFebruary 14, 2025 | gurufocus.comHighbridge Capital Management LLC Acquires Significant Stake in OnKure Therapeutics IncFebruary 7, 2025 | gurufocus.comJonesTrading Reaffirms Their Buy Rating on OnKure Therapeutics (OKUR)February 6, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military Spending3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialNew Tariffs May Bring Liberation to These 3 Steel StocksBy Gabriel Osorio-Mazilli | April 7, 2025View New Tariffs May Bring Liberation to These 3 Steel StocksCLRB, OKUR, CUE, and APLT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.32 0.00 (-0.97%) Closing price 04/10/2025 04:00 PM EasternExtended Trading$0.33 +0.02 (+4.76%) As of 04/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Cellectar Biosciences NASDAQ:CLRB$0.27 +0.03 (+11.03%) Closing price 04/10/2025 04:00 PM EasternExtended Trading$0.28 +0.00 (+1.54%) As of 04/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Cue Biopharma NASDAQ:CUE$0.72 +0.02 (+2.69%) Closing price 04/10/2025 04:00 PM EasternExtended Trading$0.74 +0.02 (+2.95%) As of 04/10/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.OnKure Therapeutics NASDAQ:OKUR$2.96 -0.19 (-6.03%) Closing price 04/10/2025 04:00 PM EasternExtended Trading$3.14 +0.19 (+6.25%) As of 04/10/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
